207 related articles for article (PubMed ID: 10652021)
1. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.
Abe A; Arend LJ; Lee L; Lingwood C; Brady RO; Shayman JA
Kidney Int; 2000 Feb; 57(2):446-54. PubMed ID: 10652021
[TBL] [Abstract][Full Text] [Related]
2. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation.
Abe A; Gregory S; Lee L; Killen PD; Brady RO; Kulkarni A; Shayman JA
J Clin Invest; 2000 Jun; 105(11):1563-71. PubMed ID: 10841515
[TBL] [Abstract][Full Text] [Related]
3. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
4. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
5. Agents for the treatment of glycosphingolipid storage disorders.
Abe A; Wild SR; Lee WL; Shayman JA
Curr Drug Metab; 2001 Sep; 2(3):331-8. PubMed ID: 11513334
[TBL] [Abstract][Full Text] [Related]
6. Improved inhibitors of glucosylceramide synthase.
Lee L; Abe A; Shayman JA
J Biol Chem; 1999 May; 274(21):14662-9. PubMed ID: 10329660
[TBL] [Abstract][Full Text] [Related]
7. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
Ashe KM; Budman E; Bangari DS; Siegel CS; Nietupski JB; Wang B; Desnick RJ; Scheule RK; Leonard JP; Cheng SH; Marshall J
Mol Med; 2015 Apr; 21(1):389-99. PubMed ID: 25938659
[TBL] [Abstract][Full Text] [Related]
9. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
Guérard N; Oder D; Nordbeck P; Zwingelstein C; Morand O; Welford RWD; Dingemanse J; Wanner C
Clin Pharmacol Ther; 2018 Apr; 103(4):703-711. PubMed ID: 28699267
[TBL] [Abstract][Full Text] [Related]
10. Regulation of phospholipase C-gamma activity by glycosphingolipids.
Shu L; Lee L; Shayman JA
J Biol Chem; 2002 May; 277(21):18447-53. PubMed ID: 11886852
[TBL] [Abstract][Full Text] [Related]
11. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
Fan JQ; Ishii S; Asano N; Suzuki Y
Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.
Meng XL; Day TS; McNeill N; Ashcraft P; Frischmuth T; Cheng SH; Liu ZP; Shen JS; Schiffmann R
J Inherit Metab Dis; 2016 May; 39(3):447-455. PubMed ID: 26960552
[TBL] [Abstract][Full Text] [Related]
13. Development of a new inhibitor of glucosylceramide synthase.
Jimbo M; Yamagishi K; Yamaki T; Nunomura K; Kabayama K; Igarashi Y; Inokuchi JI
J Biochem; 2000 Mar; 127(3):485-91. PubMed ID: 10731721
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives.
Asano N; Ishii S; Kizu H; Ikeda K; Yasuda K; Kato A; Martin OR; Fan JQ
Eur J Biochem; 2000 Jul; 267(13):4179-86. PubMed ID: 10866822
[TBL] [Abstract][Full Text] [Related]
15. Caveolar structure and protein sorting are maintained in NIH 3T3 cells independent of glycosphingolipid depletion.
Shu L; Lee L; Chang Y; Holzman LB; Edwards CA; Shelden E; Shayman JA
Arch Biochem Biophys; 2000 Jan; 373(1):83-90. PubMed ID: 10620326
[TBL] [Abstract][Full Text] [Related]
16. Chaperone Therapy in Fabry Disease.
Weidemann F; Jovanovic A; Herrmann K; Vardarli I
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
[TBL] [Abstract][Full Text] [Related]
17. Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.
Heare T; Alp NJ; Priestman DA; Kulkarni AB; Qasba P; Butters TD; Dwek RA; Clarke K; Channon KM; Platt FM
J Inherit Metab Dis; 2007 Feb; 30(1):79-87. PubMed ID: 17189993
[TBL] [Abstract][Full Text] [Related]
18. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin.
Platt FM; Reinkensmeier G; Dwek RA; Butters TD
J Biol Chem; 1997 Aug; 272(31):19365-72. PubMed ID: 9235935
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
[TBL] [Abstract][Full Text] [Related]
20. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase.
Nicholson KM; Quinn DM; Kellett GL; Warr JR
Br J Cancer; 1999 Oct; 81(3):423-30. PubMed ID: 10507766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
